Switching or restarting of tumour necrosis factor-a inhibitors after interruption under daily-life conditions: efficacy report from the Austrian Psoriasis Registry (PsoRA). Wolf, P; Weger, W; Richter, L; Mlynek A; Sator, P; Saxinger, W; Ratzinger, G; Kölli, C; Painsi, C; Bangert, C; Tatarski, R; Schütz-Bergmayr, M; Ponholzer, P; Trautinger, F; Strohal, R; Müllegger, R; Inzinger, M; Lichem, R; Salmhofer, W; Quehenberger, F. Presented at Psoriasis Gene to Clinic, 8th International Congress. The Queen Elizabeth II Conference Centre, London, U.K., 30th November – 2nd December 2017. Br J Dermatol 2017;177, ppe235–e307
Psoriasis Area and Severity Index 75 rate of classical inpatient dithranol therapy under daily life conditions. Painsi, C; Patscheider, M; Inzinger, M; Huegel, R; Lange-Asschenfeldt, B; Quehenberger, F; Wolf, P; Br J Dermatol 2015; 173:815-817
Drug adherence of tumor necrosis factor-α-inhibitors in the treatment of plaque psoriasis under daily life conditions in Austria. Inzinger, M; Wippel-Slupetzky, K; Weger, W; Wolf, P for the PsoRA Study Group; Abstracts of the 23rd Congress of the European Academy of Dermatology and Venereology; OCT 08-12, 2014; Amsterdam, Netherlands
Intermediate to long-term efficacy of tumor necrosis factor (TNF)-α inhibitors in the treatment of plaque psoriasis under daily life conditions in Austria. Inzinger, M; Wippel-Slupetzky, K; Weger, W; Wolf, P for the PsoRA Study Group; Abstracts of the 23rd Congress of the European Academy of Dermatology and Venereology; OCT 08-12, 2014; Amsterdam, Netherlands
Survival to adalimumab, etanercept, infliximab and ustekinumab in the treatment of plaque psoriasis under daily life conditions: report from Psoriasis Registry Austria. Inzinger, M; Wippel-Slupetzky, K; Weger, W; Wolf, P for the PsoRA Study Group; Abstractband 2014; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 21-23, 2014; Vienna, Austria
Reported comorbitities in patients with psoriasis who are enrolled in the Psoriasis Registry Austria (PsoRA). Inzinger, M; Weger, W; Wippel-Slupetzky, K; Wolf, P for the PsoRA Study Group; Abstractband 2014; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 21-23, 2014; Vienna, Austria
Drug survival of ustekinumab in the treatment of psoriasis under daily life condidions: report from Psoriasis Registry Austria. Weger, W; Inzinger, M; Wippel-Slupetzky, K; Wolf, P for the PsoRA Study Group; Abstractband 2014; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 21-23, 2014; Vienna, Austria
PASI-Reduktion bei Cignolin-Therapie. Painsi, C; Patscheider, M; Inzinger, M; Quehenberger, F; Lange-Asschenfeldt, B; Wolf, P; Abstractband 2013; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 22-24, 2013; Vienna, Austria
Patientenzufriedenheit und Wirksamkeit bei stationärer Cignolin-Therapie. Painsi, C; Patscheider, M; Inzinger, M; Quehenberger, F; Lange-Asschenfeldt, B; Wolf, P; Abstractband 2013; Jahrestagung der Österreichischen Gesellschaft für Dermatologie und Venerologie; NOV 22-24, 2013; Vienna, Austria
Intermediate to long-term efficacy and safety of etanercept: report from the psoriasis registry Austria. Inzinger, M; Roschatt, I; Weger, W; Salmhofer, W; Wolf, P; J Invest Dermatol 2012; 132: S60-S60. 42nd Annual Meeting of the European Society for Dermatological Research (ESDR); SEP 07-10, 2012; Venice, Italy